SupportLoginSign Up
Featured FeedJournalsCollectionsKeywordsSaved Papers
Comment
Journal Article
Research Support, N.I.H., Extramural
Add like
Add dislike
Add to saved papers

SETting OP449 into the PP2A-activating drug family.

Paolo Neviani, Danilo Perrotti
Clinical Cancer Research 2014 April 16
The protein phosphatase 2A (PP2A) tumor suppressor is inactivated in different leukemias through the activity of its endogenous inhibitors (e.g., SET), which are aberrantly regulated by oncogenic tyrosine kinases. Like other effective and nontoxic PP2A-activating drugs (PAD), OP449 inhibits SET and impairs leukemogenesis. This further supports the immediate use of PADs in patients with leukemia.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Show additional links to paperHide additional links to paper
PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app